GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,296 | -38,647 | -259,186 | -144,172 | 9,768 |
| Depreciation Amortization | 317 | 509 | 9,746 | 4,916 | 2,898 |
| Accounts payable and accrued liabilities | -838 | 3,154 | N/A | N/A | 2,813 |
| Other Working Capital | 17,065 | 2,938 | 111 | 1,405 | 2,813 |
| Other Operating Activity | 4,490 | 28,387 | 238,652 | 132,421 | -20,222 |
| Operating Cash Flow | $-7,262 | $-3,659 | $-10,677 | $-5,430 | $-1,930 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | 200 | -36 | -4 | N/A |
| Investing Cash Flow | $N/A | $200 | $-36 | $-4 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 12,531 | 3,527 | 15,145 | 5,991 | 1,902 |
| Debt Repayment | N/A | -100 | -4,415 | N/A | N/A |
| Other Financing Activity | 0 | 0 | -533 | 0 | 0 |
| Financing Cash Flow | $12,531 | $3,427 | $10,197 | $5,991 | $1,902 |
| Beginning Cash Position | 28 | 60 | 576 | 19 | 47 |
| End Cash Position | 5,297 | 28 | 60 | 576 | 19 |
| Net Cash Flow | $5,269 | $-32 | $-516 | $557 | $-28 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,262 | -3,659 | -10,677 | -5,430 | -1,930 |
| Capital Expenditure | N/A | N/A | -36 | -4 | N/A |
| Free Cash Flow | -7,262 | -3,659 | -10,713 | -5,434 | -1,930 |